2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1835

Frequency and Predictors of Meaningful Decline in Forced Vital Capacity During Follow up оf a Large Cohort of Systemic Sclerosis Associated Pulmonary Fibrosis Patients
Abstract Number: 411

Frequency and Staining Patterns of Antinuclear Antibodies in Myositis Patients Without Known Myositis-specific Autoantibodies
Abstract Number: 2701

Frequency of Juvenile Idiopathic Arthritis (JIA) Subgroups and JIA-associated Uveitis Among JIA Patients Admitted to Referral Pediatric Rheumatology Clinics In TurkEy: A Retrospective Study, JUPITER
Abstract Number: 361

Frequency of Allopurinol Dose Reduction in Hospitalized Patients with Gout Flares
Abstract Number: 408

Frequency of Concomitant Non-aminoacyl-transfer-RNA Synthetase Autoantibodies in Patients with Antisynthetase Syndrome
Abstract Number: 600

Frequency of Disease Flares Under Long-Term Anti-TNF Therapy in Patients with Early Axial Spondyloarthritis: Results from the Etanercept versus Sulfasalazine in Early Axial Spondyloarthritis Trial (ESTHER)
Abstract Number: 265

Frequency of Performing Anti dsDNA Antibody in an ANA Negative Patient with Clinical Suspicion of SLE in a Single Centre Trial Before and After the Publication of National Guideline
Abstract Number: 2150

Frequency of Polyautoimmunity in a Tertiary Hospital
Abstract Number: 281

Frequency of Ultrasound Features of Knee Osteoarthritis and Their Association with Radiographic Features and Symptoms in a Community-Based Cohort
Abstract Number: 894

Frequency, Severity and Costs of Flares Increase with Disease Severity in Newly Diagnosed Systematic Lupus Erythematous: A Real-World Cohort Study, United States, 2004–2015
Abstract Number: 1168

Frequently Encountered Artifacts in Novel Application of Dual-Energy CT to Vascular Imaging: A Pilot Study
Abstract Number: 2889

From a Potential Solution to Part of the Problem: Analysis of Spending and Price Trends for Brand-Name and Generic Colchicine and Other Gout Medications
Abstract Number: PP01

From Diagnosis to the Establishment of the Labalaba Foundation: My Journey from Surviving to Thriving
Abstract Number: 1981

Functional Differences Between Osteoclasts and Osteoclast-like Cells Differentiated from Peripheral Blood Mononuclear Cells in Patients with Rheumatoid Arthritis
Abstract Number: 2171

Functional Exercise for Adults with Chronic Nonspecific Low Back Pain

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].